Babushok DV, Bessler M. Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol. 2015;28:55–68.

Article  PubMed  Google Scholar 

Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021;39:3328–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, et al. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). J Clin Oncol. 2021;39:3318–27.

Article  PubMed  Google Scholar 

Chillemi G, Kehrloesser S, Bernassola F, Desideri A, Dötsch V, Levine AJ, et al. Structural Evolution and Dynamics of the p53 Proteins. Cold Spring Harb Perspect Med. 2017;7:a028308.

Article  PubMed  PubMed Central  Google Scholar 

Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014;38:751–5.

Article  CAS  PubMed  Google Scholar 

Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30:666–73.

Article  CAS  PubMed  Google Scholar 

Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020;4:482–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Y, Chen W, Yu J, Pei S, Zhang Q, Shi J, et al. TP53 in MDS and AML: Biological and clinical advances. Cancer Lett. 2024;588:216767.

Article  CAS  PubMed  Google Scholar 

Versluis J, Lindsley RC. Transplant for TP53-mutated MDS and AML: because we can or because we should? Hematology Am Soc Hematol Educ Program. 2022;2022:522–7.

Article  PubMed  PubMed Central  Google Scholar 

Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, Telatar M, et al. Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. Haematologica. 2017;102:2030–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou C, Zheng F, Xu L, Zhang X, Chang Y, Mo X, et al. Mutation of the TP53 gene in acute lymphoblastic leukemia does not affect survival outcomes after haploidentical hematopoietic stem cell transplantation. Int J Cancer. 2023;152:977–85.

Article  CAS  PubMed  Google Scholar 

Huang T, Xu L, Zhang X, Chang Y, Mo X, Sun Y, et al. Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia. Br J Haematol. 2023;200:494–505.

Article  CAS  PubMed  Google Scholar 

Chen WM, Liu H, Li LD, Long LY, Lai YY, Shi HX, et al. [Clinical, molecular and cytogenetic characteristics of newly diagnosed adult acute myeloid patients with TP53 gene mutation]. Zhonghua Xue Ye Xue Za Zhi. 2019;40:528–31.

CAS  PubMed  Google Scholar 

Xu Z, Mo X, Kong Y, Wen Q, Han T, Lyu M, et al. Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial. J Transl Int Med. 2023;11:255–64.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 2024;605:217264.

Article  CAS  PubMed  Google Scholar 

Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25.

Article  CAS  PubMed  Google Scholar 

Liu YR, Zhang LP, Chang Y, Cheng YF, Fu JY, Li LD, et al. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2006;27:302–5.

CAS  PubMed  Google Scholar 

Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017;376:536–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim M, Yahng SA, Kwon A, Park J, Jeon YW, Yoon JH, et al. Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation. Bone Marrow Transplant. 2015;50:1132–4.

Article  CAS  PubMed  Google Scholar 

Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, et al. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2016;34:3627–37.

Article  PubMed  PubMed Central  Google Scholar 

Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32:2691–8.

Article  PubMed  PubMed Central  Google Scholar 

Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, et al. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018;131:2989–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang F, Wang Y, Wang Y, Jin J, Han W, Chen Y, et al. The clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for patients with therapy-related myelodysplastic syndrome: comparable to de novo myelodysplastic syndrome. Clin Exp Med. 2024;24:33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136:2812–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, et al. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol. 2021;18:1172–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH, et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant. 2012;47:1099–104.

Article  CAS  PubMed  Google Scholar 

Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119:3256–62.

Article  CAS  PubMed  Google Scholar 

Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139:2347–54.

Article